IE 11 is not supported. For an optimal experience visit our site on another browser.

Berkeley Lovelace Jr.

Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.

Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.

Latest from Berkeley Lovelace Jr.

FDA approves controversial new drug designed to slow the progress of ALS

The Food and Drug Administration on Thursday approved a new drug to slow the progression of ALS, a fatal neurodegenerative disease for which there is no cure.
4d ago

Experimental Alzheimer's drug shows benefits in phase 3 trial, company says

Alzheimer's drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
11d ago

The Inflation Reduction Act aims to lower drug costs — but here’s how Big Pharma could get around it

The Inflation Reduction Act has provisions to lower drug costs, but it's possible that pharma companies could get around them, and keep drug prices high.
16d ago

1 in 5 households has medical debt. That includes people with private insurance.

Medical debt is leaving many people in the U.S. unable to afford groceries or pay their mortgages, even among the insured, research published Friday has found.
17d ago

'Gaming' of U.S. patent system is keeping drug prices sky high, report says 

Pharmaceutical companies can extend their drug patents, keeping generics off the market, in a process known as "evergreening." A report from the non-profit I-MAK details recent examples.
24d ago

'Don't wait' to get the new Covid shot, White House says

The White House is pushing Americans to get the updated Covid booster ahead of a potential fall surge of the virus. The new shots target the BA.5 omicron subvariant.
24d ago

In reversal, FDA panel votes to recommend experimental ALS drug

An FDA advisory panel voted to recommend a drug for ALS, reversing a decision from earlier this year. The drug was funded in part by the Ice Bucket Challenge.
25d ago

New Covid boosters look a lot like the old ones. Doctors worry that could lead to errors.

Experts are concerned that the updated Covid boosters look too similar to previous versions of the vaccine, and people could receive the wrong dose in error.
30d ago

CDC recommends Pfizer's and Moderna's new Covid boosters

The CDC's advisory committee endorsed updated omicron Covid boosters. The boosters target the BA.5 variant and were rapidly developed over the summer.
32d ago

FDA authorizes Pfizer's and Moderna's updated Covid booster shots

The Food and Drug Administration authorized Pfizer and Moderna's updated Covid boosters, which target the BA.5 omicron subvariant.
32d ago

FDA expected to authorize new Covid boosters without data from tests in people

The updated Covid booster could be available around Labor Day. How well will the new Covid vaccines work against omicron?